Hormone replacement therapy after surgery for epithelial ovarian cancer
Referencias
Additional references
Benkhadra K, Mohammed K, Nofal AA, Leon BC, Alahdab F, Faubion S, et al. Menopausal hormone therapy and mortality: a systematic review and meta‐analysis. Journal of Clinical Endocrinology & Metabolism 2015;100(11):4021‐8.
Biglia N, Bounous VE, Sgro LG, D’Alonzo M, Gallo M. Treatment of climacteric symptoms in survivors of gynaecological cancer. Maturitas 2015;82(3):296‐8.
Biliatis I, Thomakos N, Rodolakis A, Akrivos N, Zacharakis D, Antsaklis A. Safety of hormone replacement therapy in gynaecological cancer survivors. Journal of Obstetrics and Gynaecology 2012;32:321‐5.
Collaborative Group on Epidemiological Studies of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta‐analysis of 52 epidemiological studies. Lancet 2015;385:1835‐42.
Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta‐analysis. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care: Meta‐Analysis in Context. 2nd Edition. London (UK): BMJ Publication Group, 2001.
DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7:177‐88.
Eeles RA, Tan S, Wiltshaw E, Fryatt I, A'Hern RP, Shepherd JH, et al. Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ 1991;302(6771):259‐62.
Fleming G, Seidman J, Lengyel E. Epithelial ovarian cancer. In: Barakat RR, Berchuck A, Markman M, Randall ME editor(s). Principles and Practice of Gynecologic Oncology. 6th Edition. Philadelphia (PA): Lippincott Williams & Wilkins, 2013:757‐847.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Available from globocan.iarc.fr, accessed on 6 January 20172013.
Guidozzi F, Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer 1999;86(6):1013‐8.
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;357:557‐60.
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Hopkins ML, Fung MF, Le T, Shorr R. Ovarian cancer patients and hormone replacement therapy: a systematic review. Gynecologic Oncology 2004;92(3):827‐32.
Ibeanu O, Modesitt SC, Ducie J, von Gruenigen V, Agueh M, Fader AN. Hormone replacement therapy in gynecologic cancer survivors: why not?. Gynecologic Oncology 2011;122(2):447‐54.
Langendam MW, Akl EA, Dahm P, Glasziou P, Guyatt G, Schunemann HJ. Assessing and presenting summaries of evidence in Cochrane Reviews. Systematic Reviews 2013;23(2):81.
Leeper K, Garcia R, Swisher E, Goff B, Greer B, Paley P. Pathologic findings in prophylactic oophorectomy specimens in high‐risk women. Gynecologic Oncology 2002;87(1):52‐6.
Li L, Pan Z, Gao K, Zhang W, Luo Y, Yao Z, et al. Impact of post‐operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncology Letters 2012;3(1):244‐9.
Li D, Ding C‐y, Qiu L‐h. Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta‐analysis. Gynecologic Oncology 2015;139(2):355‐62.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine 2009;6:e1000100.
Lowe KA, Chia VM, Taylor A, O'Malley C, Kelsh M, Mohamed M, et al. An international assessment of ovarian cancer incidence and mortality. Gynecologic Oncology 2013;130(1):107‐14.
Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews 2012, Issue 7. [DOI: 10.1002/14651858.CD004143.pub4]
Mascarenhas C, Lambe M, Bellocco R, Bergfeldt K, Riman T, Persson I, et al. Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. International Journal of Cancer 2006;119(12):2907‐15.
Meader N, King K, Llewellyn A, Norman G, Brown J, Rodgers M, et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Systematic Reviews 2014;3:82.
Michaelson‐Cohen R, Beller U. Managing menopausal symptoms after gynecological cancer. Current Opinion in Oncology 2009;21(5):407‐11.
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815‐34.
Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glaziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration. 2011. Available from handbook.cochrane.org.
Singh P, Oehler MK. Hormone replacement after gynaecological cancer. Maturitas 2010;65(3):190‐7.
Ursic‐Vrscaj M, Bebar S, Zakelj MP. Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. Menopause 2001;8(1):70‐5.
Wen Y, Huang H, Wu M, Shen K, Pan L. The safety of postoperative hormone replacement therapy in epithelial ovarian cancer patients in China. Climacteric 2013;16(6):673‐81.
Zhou B, Sun Q, Cong R, Gu H, Tang N, Yang L, et al. Hormone replacement therapy and ovarian cancer risk: a meta‐analysis. Gynecologic Oncology 2008;108(3):641‐51.
